Financials in USD. Standardized financial statements.
A compact view of how Oncopeptides AB (publ) turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $31.65M | $35.22M | $8.36M | $118.30M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | -10.1% | +321.5% | -92.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $2.66M | -$1.08M | $6,000 | $53.12M | $14.40M | $4.54M | $345,000 | $271,000 | $24,074 | $0 |
| Gross Profit? | $28.98M | $36.30M | $8.35M | $65.17M | -$14.40M | -$4.54M | -$345,000 | -$271,000 | -$24,074 | $0 |
| Gross Margin? | +91.6% | +103.1% | +99.9% | +55.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $312.48M | $289.75M | $357.70M | $1.49B | $1.59B | $739.39M | $419.30M | $247.62M | $114.48M | $53.35M |
| Operating Income? | -$283.50M | -$253.45M | -$349.35M | -$1.42B | -$1.59B | -$739.39M | -$419.30M | -$247.62M | -$114.48M | -$53.35M |
| EBITDA? | -$283.50M | -$231.62M | -$319.64M | -$1.41B | -$1.51B | -$743.19M | -$419.79M | -$247.35M | -$114.46M | -$53.34M |
| Income Before Tax | -$284.21M | -$248.45M | -$337.68M | -$1.42B | -$1.59B | -$739.92M | -$419.30M | -$247.62M | -$114.45M | -$53.34M |
| Income Tax Expense | $398,000 | $664,000 | $271,000 | $8.95M | $2.25M | $785,000 | $147,000 | -$38,000 | $36,376 | $10,000 |
| Net Income? | -$284.61M | -$249.11M | -$337.95M | -$1.43B | -$1.59B | -$740.71M | -$419.45M | -$247.62M | -$114.45M | -$53.34M |
| EPS? | $-1.87 | $-2.76 | $-4.11 | $-19.00 | $-25.57 | $-14.33 | $-9.77 | $-6.39 | $-2.95 | $-1.37 |
| Diluted EPS? | $-1.87 | $-2.76 | $-4.11 | $-19.00 | $-25.57 | $-14.33 | $-9.77 | $-6.39 | $-2.95 | $-1.37 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality